Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L I Gordon

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Experimental Hematology|February 1, 1984
Estimation of hemopoietic potential by CFU-c and bone marrow scan in cancer patientsO Kucuk, L I Gordon, M S Kies, et al.
Cancer|January 15, 1993
A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: a phase II trial of the eastern Cooperative Oncology GroupL I Gordon, J Andersen, S Gregory, et al.
Cancer|February 1, 1995
Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup studyL I Gordon, J Andersen, J Colgan, et al.
Cutis|April 1, 1987
Successfully treated Hodgkin's disease followed by mycosis fungoides: case report and review of the literatureD Kaufman, L I Gordon, D Variakojis, et al.
The Journal of Clinical Investigation|July 1, 1979
Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationL I Gordon, S D Douglas, N E Kay, et al.
Science (New York, N.Y.)|September 11, 2007
Temporal trends in deep ocean redfield ratiosJ Z Zhang, C W Mordy, L I Gordon, et al.
Leukemia & Lymphoma|January 24, 2003
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan, L A Peterson, S A Kent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOML I Gordon, J Anderson, T M Habermann, et al.
Seminars in Oncology|June 1, 1980
Importance of substaging of stage III Hodgkin's diseaseH M Golomb, D L Sweet, J E Ultmann, et al.
Lipids|September 1, 1994
Inhibition of cytolytic T lymphocyte activity by oxysterolsO Küçük, J Stoner-Picking, S Yachnin, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Experimental Hematology|February 1, 1984
Estimation of hemopoietic potential by CFU-c and bone marrow scan in cancer patientsO Kucuk, L I Gordon, M S Kies, et al.
Cancer|January 15, 1993
A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: a phase II trial of the eastern Cooperative Oncology GroupL I Gordon, J Andersen, S Gregory, et al.
Cancer|February 1, 1995
Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup studyL I Gordon, J Andersen, J Colgan, et al.
Cutis|April 1, 1987
Successfully treated Hodgkin's disease followed by mycosis fungoides: case report and review of the literatureD Kaufman, L I Gordon, D Variakojis, et al.
The Journal of Clinical Investigation|July 1, 1979
Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationL I Gordon, S D Douglas, N E Kay, et al.
Science (New York, N.Y.)|September 11, 2007
Temporal trends in deep ocean redfield ratiosJ Z Zhang, C W Mordy, L I Gordon, et al.
Leukemia & Lymphoma|January 24, 2003
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan, L A Peterson, S A Kent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOML I Gordon, J Anderson, T M Habermann, et al.
Seminars in Oncology|June 1, 1980
Importance of substaging of stage III Hodgkin's diseaseH M Golomb, D L Sweet, J E Ultmann, et al.
Lipids|September 1, 1994
Inhibition of cytolytic T lymphocyte activity by oxysterolsO Küçük, J Stoner-Picking, S Yachnin, et al.
Pageof 8